Agonists of luteinizing hormone-releasing hormone in prostate cancer

Ferenc G. Rick, Norman L Block, Andrew V Schally

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Introduction: Androgen deprivation therapy (ADT) has been the first-line standard of care for treating patients with hormone-sensitive advanced prostate cancer (PCa) for many decades. The agonists of luteinizing hormone-releasing hormone (LHRH), also called gonadotropin-releasing hormone, are still the most frequently used form of medical ADT. Areas covered: This article reviews the available data and most recent information concerning the use of LHRH agonists in advanced PCa. This article also reviews the discovery and development of LHRH agonists and summarizes the clinical evidence for their efficacy in PCa. Expert opinion: The introduction and application of agonists of LHRH has modernized and improved the treatment of advanced PCa. The life-saving benefits of LHRH agonists are well established, yet underestimated. Despite their efficacy, agonists of LHRH have several disadvantages or drawbacks including disease flare. The approach to ADT has been recently further refined with the development of the LHRH antagonist degarelix. Degarelix, a highly clinically effective third-generation LHRH antagonist, is currently available in most countries for therapy of advanced PCa. This new drug offers attractive alternatives to LHRH agonists for treatment of advanced PCa. A therapy for castration-resistant PCa based on a targeted cytotoxic analog of LHRH, AEZS-108, is also emerging.

Original languageEnglish
Pages (from-to)2237-2247
Number of pages11
JournalExpert Opinion on Pharmacotherapy
Volume14
Issue number16
DOIs
StatePublished - Oct 21 2013

Fingerprint

Gonadotropin-Releasing Hormone
Prostatic Neoplasms
Androgens
Hormone Antagonists
Therapeutics
Castration
Expert Testimony
Standard of Care
Hormones

Keywords

  • Gonadotropin-releasing hormone
  • Luteinizing hormone-releasing hormone
  • Luteinizing hormone-releasing hormone antagonist
  • Metastatic prostate cancer
  • Targeted cytotoxic therapy

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology

Cite this

Agonists of luteinizing hormone-releasing hormone in prostate cancer. / Rick, Ferenc G.; Block, Norman L; Schally, Andrew V.

In: Expert Opinion on Pharmacotherapy, Vol. 14, No. 16, 21.10.2013, p. 2237-2247.

Research output: Contribution to journalArticle

Rick, Ferenc G. ; Block, Norman L ; Schally, Andrew V. / Agonists of luteinizing hormone-releasing hormone in prostate cancer. In: Expert Opinion on Pharmacotherapy. 2013 ; Vol. 14, No. 16. pp. 2237-2247.
@article{165da41c2fa54da7b735f0ea15cd8ee2,
title = "Agonists of luteinizing hormone-releasing hormone in prostate cancer",
abstract = "Introduction: Androgen deprivation therapy (ADT) has been the first-line standard of care for treating patients with hormone-sensitive advanced prostate cancer (PCa) for many decades. The agonists of luteinizing hormone-releasing hormone (LHRH), also called gonadotropin-releasing hormone, are still the most frequently used form of medical ADT. Areas covered: This article reviews the available data and most recent information concerning the use of LHRH agonists in advanced PCa. This article also reviews the discovery and development of LHRH agonists and summarizes the clinical evidence for their efficacy in PCa. Expert opinion: The introduction and application of agonists of LHRH has modernized and improved the treatment of advanced PCa. The life-saving benefits of LHRH agonists are well established, yet underestimated. Despite their efficacy, agonists of LHRH have several disadvantages or drawbacks including disease flare. The approach to ADT has been recently further refined with the development of the LHRH antagonist degarelix. Degarelix, a highly clinically effective third-generation LHRH antagonist, is currently available in most countries for therapy of advanced PCa. This new drug offers attractive alternatives to LHRH agonists for treatment of advanced PCa. A therapy for castration-resistant PCa based on a targeted cytotoxic analog of LHRH, AEZS-108, is also emerging.",
keywords = "Gonadotropin-releasing hormone, Luteinizing hormone-releasing hormone, Luteinizing hormone-releasing hormone antagonist, Metastatic prostate cancer, Targeted cytotoxic therapy",
author = "Rick, {Ferenc G.} and Block, {Norman L} and Schally, {Andrew V}",
year = "2013",
month = "10",
day = "21",
doi = "10.1517/14656566.2013.834328",
language = "English",
volume = "14",
pages = "2237--2247",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Informa Healthcare",
number = "16",

}

TY - JOUR

T1 - Agonists of luteinizing hormone-releasing hormone in prostate cancer

AU - Rick, Ferenc G.

AU - Block, Norman L

AU - Schally, Andrew V

PY - 2013/10/21

Y1 - 2013/10/21

N2 - Introduction: Androgen deprivation therapy (ADT) has been the first-line standard of care for treating patients with hormone-sensitive advanced prostate cancer (PCa) for many decades. The agonists of luteinizing hormone-releasing hormone (LHRH), also called gonadotropin-releasing hormone, are still the most frequently used form of medical ADT. Areas covered: This article reviews the available data and most recent information concerning the use of LHRH agonists in advanced PCa. This article also reviews the discovery and development of LHRH agonists and summarizes the clinical evidence for their efficacy in PCa. Expert opinion: The introduction and application of agonists of LHRH has modernized and improved the treatment of advanced PCa. The life-saving benefits of LHRH agonists are well established, yet underestimated. Despite their efficacy, agonists of LHRH have several disadvantages or drawbacks including disease flare. The approach to ADT has been recently further refined with the development of the LHRH antagonist degarelix. Degarelix, a highly clinically effective third-generation LHRH antagonist, is currently available in most countries for therapy of advanced PCa. This new drug offers attractive alternatives to LHRH agonists for treatment of advanced PCa. A therapy for castration-resistant PCa based on a targeted cytotoxic analog of LHRH, AEZS-108, is also emerging.

AB - Introduction: Androgen deprivation therapy (ADT) has been the first-line standard of care for treating patients with hormone-sensitive advanced prostate cancer (PCa) for many decades. The agonists of luteinizing hormone-releasing hormone (LHRH), also called gonadotropin-releasing hormone, are still the most frequently used form of medical ADT. Areas covered: This article reviews the available data and most recent information concerning the use of LHRH agonists in advanced PCa. This article also reviews the discovery and development of LHRH agonists and summarizes the clinical evidence for their efficacy in PCa. Expert opinion: The introduction and application of agonists of LHRH has modernized and improved the treatment of advanced PCa. The life-saving benefits of LHRH agonists are well established, yet underestimated. Despite their efficacy, agonists of LHRH have several disadvantages or drawbacks including disease flare. The approach to ADT has been recently further refined with the development of the LHRH antagonist degarelix. Degarelix, a highly clinically effective third-generation LHRH antagonist, is currently available in most countries for therapy of advanced PCa. This new drug offers attractive alternatives to LHRH agonists for treatment of advanced PCa. A therapy for castration-resistant PCa based on a targeted cytotoxic analog of LHRH, AEZS-108, is also emerging.

KW - Gonadotropin-releasing hormone

KW - Luteinizing hormone-releasing hormone

KW - Luteinizing hormone-releasing hormone antagonist

KW - Metastatic prostate cancer

KW - Targeted cytotoxic therapy

UR - http://www.scopus.com/inward/record.url?scp=84885610440&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84885610440&partnerID=8YFLogxK

U2 - 10.1517/14656566.2013.834328

DO - 10.1517/14656566.2013.834328

M3 - Article

C2 - 23984804

AN - SCOPUS:84885610440

VL - 14

SP - 2237

EP - 2247

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 16

ER -